2 May, 2010
In testimony to Congress, consumer group demands Avandia recall and halt to the TIDE drug safety trial
Dr. Sidney Wolfe, Director of the Health Research Group at the non-profit consumer advocacy group Public Citizen, testified that the health and safety of thousands of innocent people are being jeopardized by allowing the TIDE trial to continue. Continue reading Leading drug safety expert to Congress: Recall Avandia and stop TIDE trial
Category: Avandia FDA | Avandia News | Avandia Recall | Avandia Safety24 April, 2010
Avandia safety assessment at July meeting of joint FDA committees to lead to TIDE Trial decision.
When the FDA convenes a joint meeting of its Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory committees in July, the agency will assess the cardiovascular safety of Avandia and decide whether the controversial TIDE… Continue reading Assessment of Avandia Safety at July FDA meeting to lead to TIDE Trial decision
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report21 April, 2010
An Avandia safety study called the TIDE trial may be suspended by the FDA over Avandia heart attack risks.
Calls for an Avandia recall have been renewed over concerns that the diabetes drug increases heart risks. In February, a critical Senate report on Avandia was released following a two-year Senate Finance Committee investigation… Continue reading FDA may suspend Avandia safety study, could lead to Avandia recall
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report16 April, 2010
Authors of articles with favorable opinions of Avandia’s safety received money from Glaxo, reports The New York Times.
The New York Times reports that an analysis of Avandia research finds a “slant in articles” on the safety of the diabetes drug:
A new analysis of reviews and articles about the controversial diabetes drug… Continue reading Scientists with positive opinion of Avandia safety were paid by Glaxo, reports New York Times
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Safety23 March, 2010
FDA in Saudi Arabia suspends diabetes drug Avandia
Distribution of Avandia has been suspended for six months by the Saudi Food and Drug Authority (SFDA), linking use of the diabetes drug to adverse cardiovascular effects. A decision has not been made whether a permanent Avandia recall will follow.
“The S FDA Committee… Continue reading Avandia suspended from market by Saudi FDA
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Recall | Avandia Safety | Avandia Side Effects23 March, 2010
Avandia research study shows experts defending the diabetes drug had financial ties to GlaxoSmithKline
They discovered that 94% of the authors who defended Avandia (rosiglitazone) had financial ties to drug makers. Almost half of the financial ties amounted to a conflict of interest… Continue reading Avandia heart attack risk researchers had financial ties to drug maker, conflicts of interest
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Safety | Avandia Side Effects6 March, 2010
Avandia drug company GlaxoSmithKline defends its popular diabetes drug in a 30-page “white paper” released February 24 rejecting a recent Senate Report stating that GSK downplayed the safety risks of their diabetes treatment Avandia. The prescription drug maker attacks the Senate Finance Committee’s January 2010 report on Avandia, claiming it is inaccurate, unbalanced and gives Continue reading Avandia maker GlaxoSmithKline releases "White Paper Response" to Senate Report on Avandia
Category: Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report23 February, 2010
The U.S. Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline diabetes drug Avandia but has not reached any new conclusions. The FDA will hold a public meeting in July 2010 to discuss the risks and benefits of the Avandia, but said in the meantime doctors and patients should continue to use Avandia Continue reading FDA: No new conclusions on Glaxo's Avandia yet
Category: Avandia Cardiovascular Risk | Avandia Lawsuit | Avandia News | Avandia Recall | Avandia Safety